Cyclin D1 is a multifunctional protein that activates CDK4 and CDK6, titrates Cip/Kip CDK inhibitors to increase CDK2 activity, and modulates the function of certain transcription factors. To specifically test the importance of cyclin D1-associated kinase activity, we generated "knockin" mice expressing mutant cyclin D1 deficient in activating CDK4/6. The development of several cyclin D1-dependent compartments, including mammary glands, proceeds relatively normally in these animals, demonstrating that cyclin D1-associated kinase activity is largely dispensable for development of these tissues. Strikingly, knockin mice were resistant to breast cancers initiated by ErbB-2. These results demonstrate a differential requirement for cyclin D1-CDK4/6 kinase activity in development versus tumorigenesis and strongly support cyclin D1-dependent kinase activity as a specific therapeutic target in breast cancer.
The most well understood function of the D-type cyclins is to activate the G 1 kinases, cdk4 and cdk6, and target the retinoblastoma gene product (pRb) for phosphorylation and inactivation. pRb can suppress S phase entry, cause a transient G 1 arrest following DNA damage, and is critical in establishing terminal cell cycle withdrawal in cells exposed to differentiation or senescence-inducing signals. Each of these functions of pRb can be demonstrated in cultured cells derived from human tumors that have suffered RB1 gene inactivation. In such in vitro assays, coexpression of D type cyclins has been shown to inhibit the function of pRb, likely reflecting an oncogenic role of cyclin D1 in vivo. Two regions of cyclin D, the LxCxE pRb-binding motif, and the cyclin box, are thought to be critical for the proper function of cyclin D. Here we show that the LxCxE motif is dispensable in cyclin D1 for all functions tested, but is required by cyclin D2. This observation suggests that there is a functional difference between cyclins D1 and D2 in pRb regulation, and argues against complete functional redundancy of these D cyclins. In addition, the ability of cyclins D1 and D2 to activate cdk partners is required for induction of pRb phosphorylation and S phase entry. However, mutant forms of cyclins D1 and D2 that are incapable of activating kinase partners were still able to prevent pRb-induced senescence. Thus, D cyclins have both kinase-dependent and kinase-independent mechanisms of interfering with proliferation arrest and senescence. www.landesbioscience.com Cell Cycle 331 Multiple Functions of D-Type Cyclins
Cyclin D1 is a multifunctional, tumor-associated protein that interacts with pRb via a conserved LxCxE motif, activates a kinase partner, directs the phosphorylation of pRb, activates cyclin E-cyclin-dependent kinase 2 (cdk2) by titrating Cip/Kip cdk inhibitors, and modulates the activity of a variety of transcription factors. It is thought that some of the proproliferative function of cyclin D1 is exerted by LxCxE-dependent binding to the pRb pocket domain, which might interfere with the ability of pRb to repress transcription by recruiting cellular chromatin remodeling proteins to E2F-dependent promoters. To test the importance of the LxCxE domain in vivo, we have generated a ''knock-in'' mouse by replacing the wild-type cyclin D1 gene with a mutant allele precisely lacking the nucleotides encoding the LxCxE domain. Analysis of this mouse has shown that the LxCxE protein is biochemically similar to wild-type cyclin D1 in all tested respects. Moreover, we were unable to detect abnormalities in growth, retinal development, mammary gland development, or tumorigenesis, all of which are affected by deleting cyclin D1. Although we cannot exclude the presence of subtle defects, these results suggest that the LxCxE domain of cyclin D1 is not necessary for function despite the absolute conservation of this motif in the D-type cyclins from plants and vertebrates.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.